Skip to main content

Advertisement

Table 5 The initial recurrence patterns of gastric cancer patients receiving curative surgery with or without FLI1 hypermethylation in plasma samples according to MSI/EBV status

From: Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array

  MSI+ or EBV+ (n = 28) MSI− and EBV− (n = 65)
FLI1 hypermethylation FLI1 hypermethylation
Without n = 10 With n = 18 P value Without n = 41 With n = 24 P value
Total recurrence 6 (60.0) 9 (50.0) 0.611 15 (36.6) 14 (58.3) 0.089
Locoregional recurrence 0 3 (16.7) 0.172 7 (17.1) 7 (29.2) 0.252
Hepatoduodenal ligament 0 1 (5.6) 0.448 2 (4.9) 3 (12.5) 0.266
Abdominal wall 0 2 (11.1) 0.274 4 (9.8) 5 (20.8) 0.212
Perigastric area 0 0 1 (2.4) 0 0.441
Anastomosis 1 (10.0) 4 (22.2) 0.418 3 (7.3) 2 (8.3) 0.882
Distant metastasis 5 (50.0) 6 (33.3) 0.387 11 (26.8) 10 (41.7) 0.217
Peritoneal dissemination 1 (10.0) 2 (11.1) 0.927 7 (17.1) 3 (12.5) 0.622
Hematogenous metastasis 4 (40.0) 3 (16.7) 0.172 2 (4.9) 5 (20.8) 0.045
Liver 2 (20.0) 3 (16.7) 0.825 0 4 (16.7) 0.007
Lung 2 (20.0) 0 0.119 2 (4.9) 0 0.272
Bone 1 (10.0) 0 0.172 2 (4.9) 1 (4.2) 0.895
Distant lymphatic recurrence 0 2 (11.1) 0.274 3 (7.3) 5 (20.8) 0.109
Virchow’s node 0 0 0 1 (4.2) 0.188
Lymphangitis carcinomatosa 0 0 2 (4.9) 0 0.272
Para-aortic lymph node 0 2 (11.1) 0.274 1 (2.4) 5 (20.8) 0.013
  1. MSI microsatellite instability, EBV Epstein-Barr virus